Go to home page
INVESTIGATOR PROFILES

Faith B. Davis, M.D.

SENIOR SCIENTIST
Ordway Research Institute

CONTACT
Signal Transduction Laboratory
Phone: (518) 641-6465
Fax: (518) 641-6304
fdavis@ordwayresearch.org


Faith B. Davis, M.D.

Research Focus

CV-1 Cells

Effect of thyroid hormone on nuclear translocation of ERK1/2 and TRβ1
The Davis laboratory, in conjunction with the laboratory of Dr. H-Y Lin, has developed a specific thyroid hormone analogue which blocks the growth-stimulating effects of thyroid hormone on cancer cells.  A recently published report documents the suppressive effects of this thyroid hormone analogue on the growth of brain tumor cells.  A collaboration with Dr. Shaker Mousa at the Albany College of Pharmacy has disclosed that thyroid hormone stimulates the growth of blood vessels, and that an inhibitor of this thyroid hormone action will also inhibit the growth of cancer cells in the presence of thyroid hormone.  Selected analogues of thyroid hormone will also inhibit thyroid hormone stimulation of cancer cell growth.  The Davis, Lin and Mousa laboratories are now collaborating on studies of the effects of thyroid hormone and selected analogues on the growth of several different cancer cell lines, including cells derived from cancers of the thyroid, kidney, prostate, brain, lung, ovary and breast.

Selected References from 2004 to present: (View)

  • Davis FB, Mousa SA, O’Connor L, Mohamed S, Lin H-Y, Cao HJ and Davis PJ.  The proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface.  Circulation Research 94:1500-1506, 2004.
  • Shih A, Zhang S, Cao HJ, Tang H-Y, Davis FB, Davis PJ and Lin H-Y.  Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-α are mediated by 3’,5’-cyclic-adenosine 5’-monophosphate-dependent protein kinase II.  Endocrinology 145:1708-1717, 2004.
  • Tang H-Y, Lin H-Y, Zhang S, Davis FB and Davis PJ.  Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor.  Endocrinology 145:3265-3272, 2004.
  • Bergh JJ, Lin H-Y, Lansing L, Mohamed SN, Davis FB, Mousa S and Davis PJ.  Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis.  Endocrinology 146:2864-2871, 2005.
  • Davis PJ, Davis FB and Cody Y.  Membrane receptors mediating thyroid hormone action.  Trends Endocrinology and Metabolism 16:429-435, 2005.
  • Cody V, Davis PJ, Davis FB.  Molecular modeling of the thyroid hormone interactions with αvβ3 integrin.  Steroids 72:165-170, 2007.
  • Davis PJ, Leonard JL, Davis FB.  Mechanisms of nongenomic action of thyroid hormone.  Frontiers in Neuroendocrinology 29:211-218, 2008.
  • Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA.  Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent.  Angiogenesis 11:269-276, 2008.
  • Davis PJ, Davis FB, Lin H-Y.  Promotion by thyroid hormone of cytoplasm-to-nucleus shuttling of thyroid hormone receptors.  Steroids 73:1013-1017, 2008.
  • Incerpi S, Davis PJ, De Vito P, Farias RN, Lin H-Y, Davis FB.  Nongenomic actions of thyroid hormone and intracellular calcium metabolism.  Clinic Rev Bone Miner Metab 6:53-61, 2008.